Abstract: Described herein are various systems, methods, and apparatus for systematic creation of isolated homogeneous colonies of cells from vector-based lineages. The vector-based lineages may originate from multiple types of viral vector families (e.g., Paramyx-oviridae, Retroviridae, Parvoviridae) or non-natural engineered vectors or a plurality of vector combinations, for example. In certain embodiments, the isolated homogeneous colonies of cells are vector-free sub-colonies; in other embodiments, the isolated homogeneous colonies of cells are homogeneous vector sub-colonies. In other embodiments, vector mixed sub-colonies are created. The disclosed systems, methods, and apparatus are useful for inducible pluripotent stem cell (iPSC) production and work by selectively binding to one or more corresponding protein markers expressed on the surface of a cell that indicate that cellular reprogramming has occurred. Software is used to automate the purification and isolation of the iPSCs produced.

Abstract: A method of managing cancer in a patient’s cerebrospinal fluid (“CSF”) forms a fluid circuit by fluidly communicating a set of catheters (“a catheter”) with the patient’s brain ventricle and the patient’s lumbar and, while controlling the flow rate of the CSF through the CSF fluid circuit, filters cancer cells from the CSF through the fluid circuit. The method also determines both a variable indicative of cancer cell concentration in the CSF, and at some point, that the variable has attained or passed through a threshold value (e.g., greater than a maximum threshold value or below a minimum threshold value). The method stops controlling the CSF flow rate in response to the variable attaining and/or passing through the threshold value. The CSF flow rate therefore preferably returns to a natural CSF flow rate of the patient after stopping control of the CSF flow rate. A system preferably performs these acts.

Abstract: Described herein are various systems, methods, and apparatus for systematic creation of isolated homogeneous colonies of cells from vector-based lineages. The vector-based lineages may originate from multiple types of viral vector families (e.g., Paramyx-oviridae, Retroviridae, Parvoviridae) or non-natural engineered vectors or a plurality of vector combinations, for example. In certain embodiments, the isolated homogeneous colonies of cells are vector-free sub-colonies; in other embodiments, the isolated homogeneous colonies of cells are homogeneous vector sub-colonies. In other embodiments, vector mixed sub-colonies are created. The disclosed systems, methods, and apparatus are useful for inducible pluripotent stem cell (iPSC) production and work by selectively binding to one or more corresponding protein markers expressed on the surface of a cell that indicate that cellular reprogramming has occurred. Software is used to automate the purification and isolation of the iPSCs produced.

Abstract: The present disclosure generally relates to a system for flowing a fluid, e.g., CSF, from a body of a patient for sampling and analysis. In some embodiments, the system can include a diagnostic module having one or more conduits for flowing fluid therethrough. The flow of the fluid through the valves can be regulated using a control board that changes an orientation of valves disposed in the conduits between a dead-end orientation and a flow-through orientation to sample and/or analyze the fluid from the system. In some embodiments, the fluid can be recirculated into the system through one or more of the valves, with sampling and recirculating occurring substantially simultaneously.

Abstract: A method to regulate patient gene expression by controllably circulating antisense oligonucleotide material (ASO) through a closed fluid circuit formed between the patient's ventricle and lumbar regions. To that end, after coupling a fluid channel between those regions, such embodiments add ASO to the fluid channel (preferably after the channel is primed with CSF) and energize a pump to controllably flow the CSF and the ASO mixed with the CSF. CSF/ASO fluid flow may be managed to localize treatment (e.g., providing deep brain distribution) while minimizing toxicity potentially caused by the ASO to certain nerves (e.g., the peripheral nerve).

Abstract: The techniques described herein provide for improved efficiency of iPSC production from biological cells. The approach achieves improved iPSC production efficiency by obtaining a set of cells whose cell cycles are synchronized at a specific, desired cell cycle phase, such as mitotic phase (also referred to as M phase). The efficacy with which such synchronized cells can be transformed into iPSCs is higher than for an arbitrary set of cells that comprises cells at a variety of different stages in their cycles. Accordingly, the approaches described herein allow efficient generation of iPSCs, thereby facilitating myriad technologies for personalized and regenerative medicine that rely upon the effective production of iPSCs.

Abstract: Presented herein are systems and methods for automatically identifying and recommending purchases (e.g., in-app purchases) to a user based on the user's personal genetic profile. In certain embodiments, offers for such purchases are conveniently presented in the same software application (e.g., smartphone app or other computing device application) in which a user securely accesses his or her personalized genetic profile test results. Also presented herein are systems and methods for computer application developers to customize apps for presentation of recommended purchases based on a user's personal genetic profile. In certain embodiments, the systems and methods described herein provide for issuing of genetically tailored notifications to one or more mobile health devices of an individual based on an assessment of the individual's genetic profile. Such notifications, for example, can assist an individual in their adherence to particular recommended regiments, such as workout regimens.

Abstract: A CSF management method and/or apparatus is used with a patient forms a CSF circuit having at least one pump and catheter. The CSF circuit is configured to control the flow of CSF in the patient's body. The method then flows, using the pump and the catheter, the patient's CSF at a given flow rate through the CSF circuit, and monitors, using a pressure sensor, the intracranial pressure in the craniospinal compartment of the patient when flowing CSF through the CSF circuit. For safety purposes, the method controls the given flow rate of the CSF in the CSF circuit as a function of the monitored intracranial pressure in the craniospinal compartment.

Abstract: A CSF management method for use with a patient forms a closed loop CSF circuit between two points on the patient's body. The CSF circuit has a therapeutic inlet to receive a therapeutic material (e.g. a drug), and a pump having a pump outlet to direct CSF along the CSF circuit. The method controls the pump to direct CSF from the pump outlet at a CSF rate that is different from the natural flow rate (i.e., the natural CSF flow rate). The therapeutic material is added to the CSF via the therapeutic input at a therapeutic rate. The CSF rate is different than the therapeutic rate and/or may be greater than the therapeutic rate. Alternative methods may control a bolus drug infusion to localize the application to a target region.

Abstract: A CSF management method for use with a patient forms a closed loop CSF circuit between two points on the patient's body. The CSF circuit has a therapeutic inlet to receive a therapeutic material (e.g. a drug), and a pump having a pump outlet to direct CSF along the CSF circuit. The method controls the pump to direct CSF from the pump outlet at a CSF rate that is different from the natural flow rate (i.e., the natural CSF flow rate). The therapeutic material is added to the CSF via the therapeutic input at a therapeutic rate. The CSF rate is different than the therapeutic rate and/or may be greater than the therapeutic rate. Alternative methods may control a bolus drug infusion to localize the application to a target region.

Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder hi a subject. For example, the disorder is a neurodegenerative disease.

Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

Abstract: Presented herein are methods of producing “personalized” secretome compositions suitable for secretome based therapy to be administered to a specific individual and/or specific group of individuals. The iPSCs and/or iPSC-derived cells, and any iPSC-derived compositions derived therefrom, are identified as compatible with a specific individual or specific group of individuals using an identification of a cell type indicative of compatibility such as an HLA match and/or ABO blood match and/or RHD blood group match. The identified compatible cells are then retrieved from a managed HLA-indexed (and/or otherwise indexed) repository or are derived from a biological sample of a suitable donor. The retrieved compatible cells are then used to derive the “personalized” iPSC-derived secretome compositions, that comprise the complete secretome or a subset of the secretome suitable for treatment of a specific individual and/or specific group of individuals.

Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.

Abstract: Presented herein are personalized compositions comprising iPSCs and/or iPSC-derived cells (cells) and methods of producing personalized compositions suitable for various therapies, including chondrogenesis therapies, to be administered to an individual or a group of individuals. The cells and/or cell lines, and any compositions derived therefrom, are identified as compatible with a specific individual or specific group of individuals using an identification of a cell type indicative of compatibility such as an HLA match. The compatible cells are then used to derive “personalized” compositions, wherein the “personalized” compositions comprise one or more cell-secreted molecules suitable for therapy. It is found herein that a composition comprising one or more iPSC-derived MSCs, iPSC-derived chondrocytes, and iPSC-derived chondrons may provide improved treatment efficacy than would be offered by bone marrow-MSCs (BM-MSCs) or compositions comprising BM-MSCs.

Abstract: Disclosed are methods for diagnosing Parkinson's disease, or identifying a risk of developing Parkinson's disease, comprising measuring the amount of a biomolecule in a blood sample, liver sample, or hepatocyte. Also disclosed are methods for preventing or treating Parkinson's disease, comprising administering a therapeutically effective plurality of hepatocytes to a subject in need thereof.

Abstract: Presented herein are systems and methods for automatically managing and filtering social media interactions and/or online content based on genetic profiles of users. These genetic profiles include identifications of genetic interests of the users and/or genetic information to which they have permitted access. Such permissioned personal genetic profiles may be used to facilitate, manage, and filter a variety of online interactions between the user and other members of various services and/or online content in order to lead to meaningful and successful real world interactions and/or to improve the relevance of online content delivered to a user.

Abstract: The disclosed technology relates generally to devices, kits, and related methods for collecting biological samples for genetic testing. In various embodiments, a DNA collection device for collecting cells from an orifice of a human subject includes an elongate arm. The DNA collection device further includes a swab head disposed at a distal end of the elongate arm, wherein the swab head is sized to at least partially enter the orifice, and wherein the swab head comprises a plurality of bristles disposed on a surface of the swab head.

Abstract: Presented herein are systems and methods of producing “universal” and/or “off-the-shelf” CAR-T compositions suitable for cancer therapy to be administered to one or more individuals. A CAR-T composition is a composition comprising one or more types of chimeric antigen receptor T cells (CAR-T). The iPSCs and/or cell lines, and any iPSC-derived CAR-T compositions derived therefrom, are identified as compatible with one or more individuals using an identification of a cell type indicative of compatibility (e.g., HLA match and/or ABO blood match and/or RHD blood match). The compatible cells are then retrieved from a managed HLA-indexed (and/or otherwise indexed) repository or are derived from a biological sample of a donor. The retrieved compatible cells are then used to derive iPSC-derived CAR-T compositions, wherein the derived compositions are suitable for therapy of one or more individuals.

Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.